-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
Adaptive designs for Phase II oncology trials
Meinhard Kieser, Stefan Englert, Geraldine Rauch
Commentary: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
Review Article: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation
-
Bisphosphonates in the adjuvant treatment of breast cancer: rationale and clinical data
Michael Gnant
Review Article: Clinical Investigation